Xilio Therapeutics eyes the fast track to the clinic with $95M in investor cash to test redesigned IL-2, CTLA-4 meds

Nicole DeFeudis

Editor

About three years after joining the search for IL-2 and CTLA-4 therapies without all those nasty side effects, Xilio Therapeutics has teed up $95 million …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Xilio Therapeutics eyes the fast track to the clinic with $95M in investor cash to test redesigned IL-2, CTLA-4 meds

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

First meeting of CDC vaccine advisors in the Kennedy era is postponed

Roche no longer wants to be where ‘DNA sequencing goes to die’

Trump’s HHS defends drug price negotiations in Novartis suit

Trump’s picks for NIH, CMS say they’ll unload industry investments

Drug packaging manufacturers brace for impact as EU chemical ban looms

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Xilio Ther­a­peu­tics eyes the fast track to the clin­ic with $95M in in­vestor cash to test re­designed IL-2, CT­LA-4 meds

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Xilio Therapeutics eyes the fast track to the clinic with $95M in investor cash to test redesigned IL-2, CTLA-4 meds